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Genomic Variation: What Does It Mean?
Abstract
New technologies have given us the ability to detect genomic variation at resolutions 50-100 times greater
than earlier tests. The good news is that we can now detect variations that help explain developmental delays,
autism, or multiple congenital anomalies in up to 20% of children. The bad news is that we can also detect
small missing or extra pieces of chromosomes that remain unexplained: that is, we don’t know whether they
have any clinical significance at all. The rapid pace of technological change may have outpaced the lab’s ability
to interpret, providers’ abilities to explain, and patients’ abilities to understand the test results. This Issue Brief
summarizes a series of studies examining the uncertainties revolving around chromosomal microarray testing,
which has become the new standard of practice in genetic testing of children with unexplained anomalies.
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Genomic Variation: What Does It Mean?
Editor’s note: New technologies have given us the ability to detect genomic 
variation at resolutions 50-100 times greater than earlier tests. The good news is 
that we can now detect variations that help explain developmental delays, autism, 
or multiple congenital anomalies in up to 20% of children. The bad news is that 
we can also detect small missing or extra pieces of chromosomes that remain 
unexplained: that is, we don’t know whether they have any clinical significance at 
all. The rapid pace of technological change may have outpaced the lab’s ability to 
interpret, providers’ abilities to explain, and patients’ abilities to understand the test 
results. This Issue Brief summarizes a series of studies examining the uncertainties 
revolving around chromosomal microarray testing, which has become the new 
standard of practice in genetic testing of children with unexplained anomalies.
Increasingly, geneticists, pediatricians and subspecialists are ordering CMA to 
diagnose children with unexplained neurodevelopmental delays. CMA can detect 
thousands of “copy number variants” throughout the genome, and yields a diagnosis 
three to five times more often than older methods of chromosome analysis. Finding 
a genetic diagnosis can often provide relief to families, target future medical care, 
facilitate access to educational interventions, and help parents understand the risk of 
recurrence in future offspring.  
•	 In	2008,	the	American	College	of	Medical	Genetics	recommended	that	CMA	
replace karyotyping as a first-line genetic test in infants and children, because of 
the test’s enhanced diagnostic abilities. CMA practice guidelines emphasize the 
importance of pre-test counseling and informed consent to ensure that families are 
prepared for the information, and can choose how much information to receive.
•	 Microarray	testing	results	fall	into	three	main	categories:	negative	(no	clinically	
significant	variation),	pathogenic	(a	variation	known	to	result	in	a	genetic	
condition),	and	“variant	of	unknown	significance	(VUS)”.	On	average,	about	10%	
of CMA results fall into the last category. 
•	 Many	VUS	results	can	be	resolved	by	genetic	testing	of	parents	to	determine	
whether a variant has been inherited or has arisen anew in the child. Although 
most variants inherited from a “normal” parent are assumed to be benign, it 
is possible that the parent has a very mild or unexpressed form of the child’s 
condition. Further, genetic testing of a parent or child may yield “incidental” 
findings not related to the reason for testing, such as a predisposition to develop 
Alzheimer disease. 
Chromosomal microarray 
analysis (CMA) replaces 
karyotyping as standard 
of care
Reiff and colleagues explored clinicians’ perspectives about ordering CMA and about 
effectively interpreting results and communicating with families. Forty clinicians who 
had ordered CMA answered an online survey and responded to a hypothetical case of 
uncertain and incidental findings in a parent.
•	 The	clinicians	had	ordered	CMA	at	least	once	from	the	Children’s	Hospital	of	
Philadelphia	between	May	2008	and	March	2011.	Respondents	were	general	
pediatricians	(27.5%),	medical	geneticists	(12.5%),	and	pediatric	subspecialists	
(60%,	including	seven	neonatologists,	five	neurologists,	four	endocrinologists,	
three developmental pediatricians, one hematologist, one gastroenterologist, one 
oncologist, one ophthalmologist, and one critical care specialist). 
•	 Not	surprisingly,	comfort	levels	differed	for	explaining	the	three	types	of	results,	
with the highest comfort levels for normal results and the lowest comfort levels for 
VUS	results.	Most	non-geneticists	reported	that	they	would	discuss	a	VUS	finding	
with a genetic specialist.
From the clinicians’ 
perspective, a need for more 
education to explain and 
interpret results
From the parents’ perspective, 
a struggle for comprehension, 
meaning, and support
To explore how families understand and give meaning to the results of CMA testing, 
Reiff and colleagues interviewed 25 families, 11 of whom had received pathogenic 
results	and	14	who	had	received	VUS	results.	The	investigators	interviewed	31	parents	
(23	mothers	and	8	fathers),	either	in-person	or	by	telephone,	whose	children	had	
undergone	CMA	testing	at	the	Children’s	Hospital	of	Philadelphia.	In	17	families,	the	
ordering physician was a geneticist; in the other eight families, a non-geneticist.
•	 Parents	receiving	both	uncertain	and	pathogenic	results	said	that	they	had	trouble	
understanding	the	result	initially	(5	VUS	and	5	pathogenic).	Four	reported	that	
they received the results initially from non-genetics professionals lacking the 
expertise to provide adequate explanation. These misunderstandings were usually 
resolved eventually by discussion with genetics experts.
•	 Receiving	results	by	telephone,	long	waits	to	see	a	geneticist	to	discuss	the	results,	
inconsistent information provided by different health professionals, and Internet 
searches based on inadequate or inaccurate information all contributed to 
difficulties in understanding the results.
•	 Many	participants,	even	when	they	understood	the	results,	still	struggled	to	
understand the meaning and potential implications of the results, and expressed a 
need for more information and explanation. A typical response was, “I understood 
what they told me, but I wish I could have found out more about what it meant.”
•	 Results	were	perceived	to	be	helpful	in	providing	a	causal	explanation	(8	pathogenic	
and	5	VUS),	and	in	anticipating	the	child’s	future	needs	(4	pathogenic	and	4	VUS).	
Many	expressed	relief	at	finding	a	causal	explanation.	However,	a	parent	who	
found out that he had the same deletion as his child reported feeling shocked and 
subsequently questioning his sense of self.
•	 Most	parents	thought	that	the	benefits	of	the	test	would	become	more	apparent	in	
the future, as more people are tested. 
•	 Several	respondents	wanted	to	connect	with	other	families	with	the	same	genetic	
variant as a potential source of emotional support. They expressed frustration 
that the hospital could not facilitate a connection with other parents because of 
privacy regulations. 
•	 Our	understanding	of	genomic	variation	is	a	rapidly	moving	target.	Labs	now	
routinely	report	new	(de-identified)	variations	to	public	databases	and	publish	
clinical	reports	of	novel	findings.	Thus,	the	interpretation	of	a	VUS	result	may	
change over time as the worldwide knowledge base grows. Further, there is some 
variability in how different labs interpret different results.
Continued on back.
POLICY IMPLICATIONS These studies highlight key challenges in the practice of genomic medicine for 
patients, families, and clinicians. The increasing use of genetic sequencing technology 
will likely magnify these problems, as we will be able to quickly describe and detect all 
human genetic variation long before we understand what most of it means for the 
individual patient. 
•	 Genetics	expertise	makes	a	big	difference	in	how	abnormal	and	uncertain 
results are delivered and received, and yet the current medical genetics workforce is 
not sufficient to meet this demand. Non-geneticists need educational resources 
to improve their ability to understand and communicate sometimes complex 
genetic findings.
Prenatal CMA has not yet supplanted karyotyping as the standard of care, but a newly 
published study has demonstrated its greater diagnostic yield. Prenatal use of CMA 
poses even more challenges because any indication of a problem with the fetus can 
transform the experience of pregnancy. To understand women’s experiences, Bernhardt 
and	colleagues	interviewed	23	women	who	had	both	karyotyping	and	CMA	as	part	
of	a	large	multicenter	study,	and	had	received	either	pathogenic	or	VUS	results.	
Telephone interviews were conducted at least six month postpartum or post- 
pregnancy termination.
•	 All	women	had	received	genetic	counseling	and	were	undergoing	an	invasive	
prenatal	diagnostic	procedure	(either	amniocentesis	or	chorionic	villus	sampling)	
for karyotype analysis. During the informed consent session, a genetic counselor 
explained the risks, benefits, and limitations of CMA testing. All women received 
their results from the genetic counselor or a study obstetrician, with follow-up 
counseling available.
•	 Initially,	receiving	abnormal	CMA	results	left	most	women	shocked,	anxious,	
confused, and overwhelmed. Many of those who had received abnormal CMA 
results after first receiving normal karyotyping results felt “blindsided.” Many 
women discussed the difficulty of emotionally and intellectually managing the 
uncertainties of results given how far along they were in their pregnancies.
•	 The	women	needed	support	to	manage,	understand,	and	act	on	the	CMA	results.	
Most women reported receiving help from the study obstetrician or genetic 
counselor, although many commented that they wanted more support with 
decision-making about continuing or terminating the pregnancy.
•	 Most	women	understood	that	CMA	could	identify	serious	problems	in	the	baby	
missed on routine cytogenetic analysis. But only one recalled being told that some 
results might be uncertain or uninterpretable. When given those results, many 
women considered this information to be knowledge they wished they did not have 
(toxic	knowledge).	Even	after	delivering	a	normal-appearing	baby,	8	of	the 
16	women	who	continued	their	pregnancies	had	lingering	worries	about	their	
child’s development.
Prenatal use of CMA poses 
even more challenges
•	 Overall,	non-geneticists	reported	a	strong	need	for	more	education	about	
interpreting and explaining CMA results. Most clinicians felt that parents’ 
understanding of CMA results was somewhat low, although geneticists rated parent 
understanding higher than non-geneticists. 
•	 While	clinical	guidelines	recommend	pre-test	counseling	to	prepare	families	for	
incidental or uncertain findings, many clinicians did not consider it pertinent 
in pre-test counseling of parents to discuss the potential for CMA to uncover 
incidental findings. This varied by specialty: all general pediatricians felt it was 
pertinent,	compared	to	60%	of	geneticists	and	39%	of	pediatric	subspecialists.
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•	 Similarly,	families	need	educational	resources	and	support	before	and	after	genetic	
testing.	Given	the	limited	number	of	genetics	professionals,	new	strategies	are	
needed to overcome long waits for genetic counseling and misinformed Internet 
searches. Parents who have been through the experience of receiving uncertain 
results may be the most available and underutilized resource for new families. 
Programs to train parents and facilitate referrals should be fostered. 
•	 Both	providers	and	patients	need	regularly	updated	resources	that	summarize	what	
is currently known about the specific “copy number variants” reported to them.
•	 In	addition	to	provider-	and	patient-level	training	and	support,	we	should	consider	
system-level interventions that improve the infrastructure for integrating genomic 
medicine into clinic care. Institutional policies should encourage compliance 
with best practice guidelines around ordering and explaining genetic test results. 
Electronic ordering systems and the electronic medical record provide opportunities 
to develop and test new, interactive ways of delivering genetics education and 
information in appropriate and timely formats to both clinicians and families.
